Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In a strategic move to reduce interest outflow, CBS Corporation ( CBS - Analyst Report ) announced the simultaneous offering and redemption of debt. The company announced a two-part offering of $400 million and $500 million priced at 1.95% due 2017 and 4.85% due 2042, respectively.
Subsequently, the company declared the redemption of its $400 million outstanding 8.2% debt due May 15, 2014 and $338 million, 5.625% debt due August 15, 2012.
The move makes perfect sense as borrowing costs have gone down despite the significant disruption in the global credit markets. In fact this is not the first time that the company has exchanged its higher-interest debt for lower-interest debt.
In February, the company took the similar stance and came up with a new debt offering of $700 million priced at 3.375% due 2022 and subsequently declared the redemption of its $700 million outstanding 6.75% debt due March 27, 2056.
Earlier, the company posted strong first-quarter 2012 results. The quarterly earnings of 54 cents a share were way ahead of the Zacks Consensus Estimate of 44 cents and surged 86% from 29 cents earned in the year-ago quarter. Revenues jumped 12% year over year to $3,924 million.
CBS Corporation ended the quarter with cash and cash equivalents of $794 million and long-term debt of $5,902 million. The company incurred interest expense of $110 million during the quarter.
Currently, we have a long-term ‘Outperform’ rating on the stock. Moreover, CBS Corp. which faces stiff competition from News Corporation ( NWSA - Analyst Report ) and Comcast Corporation ( CMCSA - Analyst Report ) , holds a Zacks #1 Rank that translates into a short-term ‘Strong Buy’ rating.
Read the full reports :
Analyst Report on NWSA
Analyst Report on CBS
Analyst Report on CMCSA